-
NEJM Editor-in-Chief Classroom: New Trends in Tumor Immunotherapy (Part I) ASCO 2021 warm-up
Time of Update: 2021-06-11
Dan Longo, the editor in charge of the New England Journal of Medicine (NEJM), to summarize the progress of tumor immunotherapy in the past three years and clarify the main lines and trends of frontier progress.
-
Sintilizumab was approved by NMPA for new indications; The Lancet revealed that lenvatinib as the first-line treatment of advanced hepatocellular carcinoma significantly delayed the deterioration of function;
Time of Update: 2021-06-11
REFLECT published by The Lancet on June 1, 2021 The results of the study showed that compared with sorafenib, lenvatinib's health-related quality of life (HRQOL) benefit evidence supports the use of lenvatinib to delay the deterioration of advanced hepatocellular carcinoma.
-
2021 ASCO prospects the development of new drugs in acute myeloid leukemia
Time of Update: 2021-06-11
Abstract 7006: Olutasidenib (FT-2102) in the treatment of relapsed and refractory mIDH1 acute myeloid leukemia: Phase II study interim analysis results Research background Oral, potent mIHD1 inhibitor Olutasidenib has shown good results in high-risk AML patients in phase I trials Tolerability and clinical activity (Watts, Blood 2019).
-
Express reduces the risk of breast cancer recurrence by 42%, and the Phase 3 clinical results of olaparib are positive
Time of Update: 2021-06-11
"Reference: [1] Lynparza reduced the risk of cancer recurrence by 42% in the adjuvant treatment of patients with germline BRCA-mutated high-risk early breast cancer in OlympiA Phase III trial.
-
Advanced Materials Significant progress!
Time of Update: 2021-06-11
In conclusion, this work not only provides the first strategy for O2−• generation guided by LAC, but also provides new insights into activatable CDT.
In short, this research not only provides the first strategy for O2-•generation guided by LAC, but also provides new insights into activatable CDT.
-
Express reduces the risk of recurrence of renal cell carcinoma by 32%, and the phase 3 results of blockbuster PD-1 inhibitors are positive
Time of Update: 2021-06-11
"Reference: [1] Merck's KEYTRUDA® (pembrolizumab) Given After Surgery Reduced the Risk of Disease Recurrence or Death by 32% Versus Placebo as Adjuvant Therapy in Patients With Renal Cell Carcinoma (RCC).
-
2021 ASCO prospective initial treatment of multiple myeloma consolidation treatment plan exploration
Time of Update: 2021-06-11
Abstract 8000: A comparative study on the efficacy of carfilzomib, cyclophosphamide, dexamethasone consolidation therapy and autologous hematopoietic stem cell transplantation in newly diagnosed MM patients Background NDMM patients usually get higher minimal residual after induction therapy and consolidation therapy The negative rate of MRD, whether these patients need autologous hematopoietic stem cell transplantation (ASCT) remains to be evaluated.
-
Cytokine storm appeared after cancer patients were vaccinated with the new crown vaccine; the bispecific antibody teclistamab was recognized as a breakthrough therapy.
Time of Update: 2021-06-11
The Lancet: The sustainability of neutralizing antibodies induced by the bivalent HPV vaccine Higher than quadrivalent vaccine JAMA Oncol: There is no significant difference in the SARS-CoV-2 antibody status between cancer patients and medical staff during the COVID-19 pandemic in Japan.
-
2021 ASCO releases latest clinical data for multiple blockbuster CAR-T therapies
Time of Update: 2021-06-11
The Phase I clinical data released by Professor Liang Aibin at this ASCO meeting are still used to evaluate the safety and efficacy of r/r B-NHL patients who have previously received anti-CD19 targeted CAR-T therapy.
-
Harvard 160,000 people study: Diabetes is associated with a nearly 40% increase in cancer risk, especially liver cancer
Time of Update: 2021-06-11
Image source: After 123RF adjusted for other factors, researchers found that type 2 diabetes was associated with a higher risk of cancer.
Compared with subjects without type 2 diabetes, having type 2 diabetes is associated with a 21% increase in overall cancer risk.
-
Early use, rapid onset, apatamide + ADT help patients with multiple bone metastases mHSPC survive longer classic cases
Time of Update: 2021-06-11
Patients with prostate cancer with multiple bone metastases who have been treated with apatamide + ADT for 1 month have a rapid PSA decline, and the effect is significant.
-
Geng Hao, Anhui Medical University, et al.: Exosomes and bladder cancer: new biomarkers and targets
Time of Update: 2021-06-11
JZUS-B welcomes outstanding scholars at home and abroad to contribute the latest scientific research results, controversial topics, review papers, and organize the publication of hot albums.
-
With a total value of US$189 million, Cinda Biologics has obtained the exclusive license of ROS1/NTRK inhibitor from Baoyuan Pharmaceutical in Greater China
Time of Update: 2021-06-11
According to the terms of the agreement, Cinda Bio will obtain the right to jointly develop and commercialize Ttaletrectinib in the Greater China Region with Baoyuan Pharmaceutical as an exclusive partner.
-
Cancer Discovery Li Jinxiu and others reveal the new formation mechanism of synovial sarcoma
Time of Update: 2021-06-11
Li Jinxiu as the first author) jointly published an article A role for SMARCB1 in synovial sarcomagenesis reveals that SS18 on Cancer Discovery -SSX induces canonical BAF destruction, using mouse models to reveal that SS18-SSX and SMARCCB1 proteins co-exist in the CABF complex and the combination of SS18-SSX leads to the degradation of CBAF, which leads to an increase in the proportion of PBAF and GBAF in synovial sarcoma cells.
-
[Industry News] The first KRAS inhibitor was approved for the market, and it may become history!
Time of Update: 2021-06-11
Click on the translational medicine website above to subscribe to our dry goods | Reliable | Practical May 28, 2021, FDA announced accelerated approval of KRAS inhibitor Lumakras (active ingredient sotorasib, AMG510) for the treatment of non-small cell lung cancer with KRAS-G12C mutation (NSCLC) patients, this is the first anti-cancer therapy targeting specific KRAS gene mutations.
-
Zhaxin: Single people are more susceptible to cancer, and the death rate after cancer is higher
Time of Update: 2021-06-11
The study shows that middle-aged men’s loneliness is associated with an increased risk of cancer, and that single men (unmarried, widowed, divorced) have a higher mortality rate for cancer patients.
-
The U.S. FDA grants Janssen the BCMA/CD dual anti-breakthrough therapy designation medical Maimeng broke
Time of Update: 2021-06-11
MedClub New Observation June 3, 2021/MedClub News/--Recently, Janssen, a subsidiary of Johnson & Johnson, announced that the FDA has granted its bispecific antibody teclistamab breakthrough therapy designation.
-
Professor Zhong Diansheng and Professor Meng Fanlu: "Talking" about the immunotherapy of advanced solid tumors, "drawing" a new way for long-term survival
Time of Update: 2021-06-11
Clinical studies have confirmed that MSI-H/ Mismatch repair deficiency (dMMR) can effectively predict whether patients with advanced solid tumors will benefit from immune checkpoint inhibitor therapy, and has nothing to do with specific cancer types [2].
-
2021 EHA prospective CD22-CAR-T cell therapy to treat adult R/R B-ALL
Time of Update: 2021-06-11
Although the current CD19-CAR-T cell therapy for relapsed or refractory acute B-lymphocytic leukemia (R/R B-ALL) has achieved a high complete remission (CR) rate, there are still some patients in CD19-CAR -The recurrence of T cell therapy and the detection of CD22 expression have become an urgent problem to be solved.
-
Professor Niu Ting: Progress in the diagnosis and treatment of diffuse large B-cell lymphoma
Time of Update: 2021-06-11
At this meeting, Professor Niu Ting from West China Hospital of Sichuan University gave a theme report on "Diffuse Large B-Cell Lymphoma (DLBCL) Diagnosis and Treatment Progress".
